Dementia

Growth of the Diagnosed prevalence Schizophrenia population will contribute to increasing sales in the therapy market over our forecast period. An estimated annual growth rate of 1.40% in the diagnosed Prevalent Schizophrenia population across the major pharmaceutical markets will contribute to increasing Schizophrenia therapy sales. In 2017, there were approximately XX million diagnosed cases of Schizophrenia in the major markets; we expect the number of cases will exceed XX million in 2030 owing to changes in population demographics and increasing cases of treatment resistant Schizophrenia.

The continuous involvement of second-generation treatments for the Schizophrenia patients will contribute to the the overall growth of the Schizophrenia therapy market and The uptake of the emerging treatments will drive significant sales growth for the Schizophrenia market through 2030.